ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Mental Health
Can psychedelics treat depression?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 205410" data-attributes="member: 13851"><p><strong>Psychedelic trips could soon be part of therapy — here’s what those sessions will look like</strong></p><p><strong></strong></p><p><strong>[ATTACH=full]15789[/ATTACH]</strong></p><p><strong>Medicinal uses for psilocybin include depression, PTSD, and other mental disorders, and as more clinical data comes in, a recent spate of public offering has raised billions of dollars for the emerging mental health field.</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Investors are opening their minds and wallets to the possibilities of psychedelic-assisted therapies.</strong></p><p><strong></strong></p><p><strong><em>Three biopharmaceutical companies aiming to make psychedelic drugs to treat mental health disorders have gone public in recent months: Peter Thiel-backed <a href="https://www.cnbc.com/quotes/9VC-FF" target="_blank">Atai Life Sciences</a> IPO’d in June and now has a market cap of <a href="https://www.cnbc.com/quotes/9VC-FF" target="_blank">$2.6 billion</a>; <a href="https://www.cnbc.com/quotes/MNMD" target="_blank">MindMed</a> went public in April and now has a market cap of more than $1 billion; and <a href="https://www.cnbc.com/quotes/CMPS" target="_blank">Compass Pathways</a> IPO’d in November, with a current market cap of nearly $1.5 billion.</em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em>Together the three companies have more than nine psychedelic therapy drugs in their pipelines. And that’s not to mention the work being done by many more private biotech and telemedicine companies like Y Combinator-backed <a href="https://www.ycombinator.com/companies/gilgamesh-pharmaceuticals" target="_blank">Gilgamesh Pharmaceuticals</a>, as well as start-ups like <a href="https://www.mindbloom.com/" target="_blank">Mindbloom</a>, which is already treating patients with ketamine-assisted psychotherapy. (Ketamine is not psychedelic but is considered a dissociative anesthetic that can lead to a distortion of sights, colors, sounds, self, and environment).</em></strong></p><p><strong><em></em></strong></p><p><strong><em>All this means that tripping on mind-altering drugs like MDMA could become a regular part of therapy to treat conditions from depression to post-traumatic stress disorder, addiction, chronic pain, and obsessive-compulsive disorder in the next two to five years.</em></strong></p><p><strong></strong></p><p><strong>Here’s what that could look like and what the research says.</strong></p></blockquote><p></p>
[QUOTE="madman, post: 205410, member: 13851"] [B]Psychedelic trips could soon be part of therapy — here’s what those sessions will look like [ATTACH type="full" alt="Screenshot (6374).png"]15789[/ATTACH] Medicinal uses for psilocybin include depression, PTSD, and other mental disorders, and as more clinical data comes in, a recent spate of public offering has raised billions of dollars for the emerging mental health field. Investors are opening their minds and wallets to the possibilities of psychedelic-assisted therapies. [I]Three biopharmaceutical companies aiming to make psychedelic drugs to treat mental health disorders have gone public in recent months: Peter Thiel-backed [URL='https://www.cnbc.com/quotes/9VC-FF']Atai Life Sciences[/URL] IPO’d in June and now has a market cap of [URL='https://www.cnbc.com/quotes/9VC-FF']$2.6 billion[/URL]; [URL='https://www.cnbc.com/quotes/MNMD']MindMed[/URL] went public in April and now has a market cap of more than $1 billion; and [URL='https://www.cnbc.com/quotes/CMPS']Compass Pathways[/URL] IPO’d in November, with a current market cap of nearly $1.5 billion. Together the three companies have more than nine psychedelic therapy drugs in their pipelines. And that’s not to mention the work being done by many more private biotech and telemedicine companies like Y Combinator-backed [URL='https://www.ycombinator.com/companies/gilgamesh-pharmaceuticals']Gilgamesh Pharmaceuticals[/URL], as well as start-ups like [URL='https://www.mindbloom.com/']Mindbloom[/URL], which is already treating patients with ketamine-assisted psychotherapy. (Ketamine is not psychedelic but is considered a dissociative anesthetic that can lead to a distortion of sights, colors, sounds, self, and environment). All this means that tripping on mind-altering drugs like MDMA could become a regular part of therapy to treat conditions from depression to post-traumatic stress disorder, addiction, chronic pain, and obsessive-compulsive disorder in the next two to five years.[/I] Here’s what that could look like and what the research says.[/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Mental Health
Can psychedelics treat depression?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top